A Multi-Site Phase I Trial of Veliparib with Standard Radiation and Temozolomide in Patients with Newly Diagnosed Glioblastoma Multiforme (GBM)

PURPOSE: A multi-site Phase I trial was conducted to determine the safety, maximum tolerated dose, and pharmacokinetics (PK) of Veliparib, a Poly (ADP-ribose) polymerase [PARP] enzyme inhibitor, when administered with temozolomide (TMZ) alone and then with temozolomide and radiation (RT) in patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Kleinberg, Lawrence, Ye, Xiaobu, Supko, Jeff, Stevens, Glenn H.J., Shu, Hui-Kuo, Mikkelsen, Tom, Lieberman, Frank, Lesser, Glenn, Lee, Emerson, Grossman, Stuart
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Journal Experts 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635324/
https://www.ncbi.nlm.nih.gov/pubmed/37961385
http://dx.doi.org/10.21203/rs.3.rs-3466927/v1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10635324/
https://www.ncbi.nlm.nih.gov/pubmed/37961385
http://dx.doi.org/10.21203/rs.3.rs-3466927/v1

Ejemplares similares